Published in J Cancer Res Clin Oncol on March 24, 2006
MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med (2009) 6.13
Interferon: the magic bullet to prevent hepatocellular carcinoma recurrence after resection? Ann Surg (2007) 1.70
Hepatocellular carcinoma: insight from animal models. Nat Rev Gastroenterol Hepatol (2011) 1.28
Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Curr Cancer Drug Targets (2012) 1.23
Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol (2015) 1.02
Pathobiological features of small hepatocellular carcinoma: correlation between tumor size and biological behavior. J Cancer Res Clin Oncol (2010) 1.01
Clinical features of hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol (2010) 1.01
The effect of alkaline phosphatase and intrahepatic metastases in large hepatocellular carcinoma. World J Surg Oncol (2013) 0.99
Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis. World J Gastroenterol (2010) 0.97
Effects of antiviral therapy on the recurrence of hepatocellular carcinoma after curative resection or liver transplantation. Hepat Mon (2012) 0.95
Inflammatory immune responses in tumor microenvironment and metastasis of hepatocellular carcinoma. Cancer Microenviron (2012) 0.94
Surgical treatment for early hepatocellular carcinoma: comparison of resection and liver transplantation. J Cancer Res Clin Oncol (2010) 0.92
Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One (2013) 0.91
Prevention of recurrence after curative treatment for hepatocellular carcinoma. Surg Today (2012) 0.90
Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis. PLoS One (2014) 0.90
Optimal adjuvant therapy for resected hepatocellular carcinoma: a systematic review with network meta-analysis. Oncotarget (2015) 0.90
Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapy. Biomark Res (2013) 0.87
Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: A meta-analysis with comparison of different types of hepatitis. Mol Clin Oncol (2014) 0.86
Effects of antiviral therapy on preventing liver tumorigenesis and hepatocellular carcinoma recurrence. World J Gastroenterol (2013) 0.85
Long-term interferon-α treatment suppresses tumor growth but promotes metastasis capacity in hepatocellular carcinoma. J Cancer Res Clin Oncol (2010) 0.85
A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma. Can J Gastroenterol (2013) 0.83
Direct transformation of lung microenvironment by interferon-α treatment counteracts growth of lung metastasis of hepatocellular carcinoma. PLoS One (2013) 0.82
Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. Int J Clin Oncol (2010) 0.82
Preventive effect of regional radiotherapy with phosphorus-32 glass microspheres in hepatocellular carcinoma recurrence after hepatectomy. World J Gastroenterol (2008) 0.82
Role of antiviral therapy in reducing recurrence and improving survival in hepatitis B virus-associated hepatocellular carcinoma following curative resection (Review). Oncol Lett (2014) 0.81
Adjuvant iodine-125 brachytherapy for hepatocellular carcinoma after complete hepatectomy: a randomized controlled trial. PLoS One (2013) 0.81
Interferon-α enhances antitumor activities of oncolytic adenovirus-mediated IL-24 expression in hepatocellular carcinoma. Mol Cancer (2012) 0.79
Anti-viral therapy to reduce recurrence and improve survival in hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol (2013) 0.79
A meta-analysis and systematic review: adjuvant interferon therapy for patients with viral hepatitis-related hepatocellular carcinoma. World J Surg Oncol (2013) 0.79
Adjuvant lipiodol I-131 after curative resection/ablation of hepatocellular carcinoma. HPB (Oxford) (2008) 0.78
Development of a miR-26 companion diagnostic test for adjuvant interferon-alpha therapy in hepatocellular carcinoma. Int J Biol Sci (2013) 0.78
Extracellular 2'5'-oligoadenylate synthetase 2 mediates T-cell receptor CD3-ζ chain down-regulation via caspase-3 activation in oral cancer. Immunology (2015) 0.78
Effect of adjuvant interferon therapy on hepatitis B virus-related hepatocellular carcinoma: a systematic review. World J Surg Oncol (2016) 0.77
Up-regulation of platelet-derived growth factor-A is responsible for the failure of re-initiated interferon alpha treatment in hepatocellular carcinoma. BMC Cancer (2012) 0.77
Thrombocytopenia for prediction of hepatocellular carcinoma recurrence: Systematic review and meta-analysis. World J Gastroenterol (2015) 0.77
Peritumoral Neuropilin-1 and VEGF receptor-2 expression increases time to recurrence in hepatocellular carcinoma patients undergoing curative hepatectomy. Oncotarget (2014) 0.77
Potentiality of immunotherapy against hepatocellular carcinoma. World J Gastroenterol (2015) 0.77
Interferon-alpha restrains growth and invasive potential of hepatocellular carcinoma induced by hepatitis B virus X protein. World J Gastroenterol (2008) 0.77
Higher proliferation of peritumoral endothelial cells to IL-6/sIL-6R than tumoral endothelial cells in hepatocellular carcinoma. BMC Cancer (2015) 0.75
Management before hepatectomy for hepatocellular carcinoma with cirrhosis. World J Hepatol (2015) 0.75
The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep (2017) 0.75
Power and sample size calculations. A review and computer program. Control Clin Trials (1990) 9.58
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med (2005) 7.18
Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med (1996) 6.01
Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet (2000) 4.60
Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet (1999) 3.54
Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology (2000) 3.42
Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg (2001) 3.25
Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg (1991) 2.46
Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist (2001) 2.22
Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma. J Am Coll Surg (2000) 2.13
Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. Arch Surg (1998) 1.54
Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med (2001) 1.53
Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol (2002) 1.52
Primary prevention of hepatocellular carcinoma. J Gastroenterol Hepatol (1996) 1.40
Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med (1999) 1.40
Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol (2003) 1.36
Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg (2002) 1.35
High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology (2000) 1.32
Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology (2004) 1.31
Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma. Aliment Pharmacol Ther (2003) 1.25
Risk factors for early death due to recurrence after liver resection for hepatocellular carcinoma: results of a multicenter study. J Surg Oncol (2004) 1.23
Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: a prospective randomized study. Semin Oncol (1997) 1.19
Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation. Oncogene (2003) 1.18
Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer (2004) 1.16
Progress and prospects in hepatocellular carcinoma surgery. Ann Chir (1998) 1.15
Postoperative adjuvant chemotherapy after radical hepatic resection for hepatocellular carcinoma (HCC). Hepatogastroenterology (1997) 1.14
Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology (1994) 1.13
Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology (1999) 1.08
Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J Gastrointest Surg (2003) 1.00
Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma. Semin Liver Dis (2005) 1.00
[Appraisal of postoperative transcatheter arterial chemoembolization (TACE) for prevention and treatment of hepatocellular carcinoma recurrence]. Zhonghua Zhong Liu Za Zhi (2000) 0.99
Interferon-alpha 2a up-regulated thymidine phosphorylase and enhanced antitumor effect of capecitabine on hepatocellular carcinoma in nude mice. J Cancer Res Clin Oncol (2004) 0.88
Quantitative HBV DNA levels as an early predictor of nonresponse in chronic HBe-antigen positive hepatitis B patients treated with interferon-alpha. J Viral Hepat (2006) 0.85
Long-term follow-up of Japanese patients with chronic hepatitis B treated with interferon-alpha. Int J Mol Med (2005) 0.84
Hepatitis B virus-related hepatocellular carcinogenesis and its prevention. Intervirology (2005) 0.82
The NIH Human Microbiome Project. Genome Res (2009) 24.61
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85
Genome-wide association studies of 14 agronomic traits in rice landraces. Nat Genet (2010) 8.75
MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med (2009) 6.13
High-throughput genotyping by whole-genome resequencing. Genome Res (2009) 5.74
EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology (2008) 5.53
Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med (2003) 5.45
Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol (2004) 5.29
Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol (2007) 5.28
Physical activity and weight gain prevention. JAMA (2010) 5.27
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med (2011) 4.91
Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology (2008) 4.50
Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell (2006) 4.33
Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol (2012) 4.21
EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res (2008) 4.17
Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology (2009) 3.92
Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys (2010) 3.87
Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol (2011) 3.80
Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov (2013) 3.64
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet (2011) 3.41
Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res (2009) 3.39
Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet (2012) 3.14
MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res (2011) 3.03
High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol (2008) 2.92
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A (2012) 2.89
HIV prevalence in China: integration of surveillance data and a systematic review. Lancet Infect Dis (2013) 2.82
Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol (2010) 2.65
A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res (2010) 2.59
A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol (2003) 2.50
The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol (2002) 2.47
TRPC channels promote cerebellar granule neuron survival. Nat Neurosci (2007) 2.47
Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages. Nat Immunol (2011) 2.47
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol (2013) 2.44
Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003-11): a national observational cohort study. Lancet (2012) 2.41
Fibrin fragment D-dimer and the risk of future venous thrombosis. Blood (2002) 2.41
Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG. Circ Res (2003) 2.27
HIV and syphilis prevalence among men who have sex with men: a cross-sectional survey of 61 cities in China. Clin Infect Dis (2013) 2.24
Telemedical retinopathy of prematurity diagnosis: accuracy, reliability, and image quality. Arch Ophthalmol (2007) 2.22
Sperm, but not oocyte, DNA methylome is inherited by zebrafish early embryos. Cell (2013) 2.16
Critical Role of STAT5 transcription factor tetramerization for cytokine responses and normal immune function. Immunity (2012) 2.16
Hepatocellular carcinoma with obstructive jaundice: diagnosis, treatment and prognosis. World J Gastroenterol (2003) 2.07
Formation of large voids in the amorphous phase-change memory Ge2Sb2Te5 alloy. Phys Rev Lett (2009) 2.06
The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World J Gastroenterol (2002) 2.03
BATF-JUN is critical for IRF4-mediated transcription in T cells. Nature (2012) 2.00
MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway. Hepatology (2014) 1.97
Estimating the number of people living with HIV/AIDS in China: 2003-09. Int J Epidemiol (2010) 1.96
A novel nuclear factor-kappaB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status. Clin Cancer Res (2007) 1.96
Study of severe and rare complications of transarterial chemoembolization (TACE) for liver cancer. Eur J Radiol (2006) 1.95
Blood 25-hydroxy vitamin D levels and incident type 2 diabetes: a meta-analysis of prospective studies. Diabetes Care (2013) 1.95
Crosstalk among Jak-STAT, Toll-like receptor, and ITAM-dependent pathways in macrophage activation. J Leukoc Biol (2007) 1.94
Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program. Arthritis Rheumatol (2014) 1.91
The genomics of selection in dogs and the parallel evolution between dogs and humans. Nat Commun (2013) 1.86
The development of HIV/AIDS surveillance in China. AIDS (2007) 1.86
Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. J Hepatol (2007) 1.86
Stepwise metastatic human hepatocellular carcinoma cell model system with multiple metastatic potentials established through consecutive in vivo selection and studies on metastatic characteristics. J Cancer Res Clin Oncol (2004) 1.86
Association of autophagy defect with a malignant phenotype and poor prognosis of hepatocellular carcinoma. Cancer Res (2008) 1.85
Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology (2013) 1.84
A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma. Cancer J (2004) 1.84